Our Strategy - Commercialising proprietary Antiviral Triple Therapy (ATT) ZIVERDOX

Topelia will deploy a model of company development that is swift, lower risk, and capital efficient in addressing a large market with unmet need.

Speed to market is critical to capturing the opportunity and value generation for Topelia and its investors. Our ability to achieve this rapid translation rests with key features built into our business model of taking our proprietary Antiviral Triple Therapy - ZIVERDOX, combining existing approved antiviral drugs to drive significant reductions in the time, cost and risk associated with the clinical and commercial development pathways to rapidly access global markets. We have developed intellectual property to protect these new applications in targeting the substantial, largely untapped markets for oral agents for COVID-19 and intend on further developing this as opportunities arise.

Topelia’s strategy is to build shareholder value by addressing the unmet needs for a safe, effective therapeutic ZIVERDOX and prophylactic ZIVERDOX for COVID-19 infection. In doing so, Topelia Australia is targeting a high growth, commercially attractive market. The global COVID-19 therapeutics market has been projected to grow to US$25.6 billion in 2030, with an estimated impressive 10.7% CAGR from 2021 to 2030.